Vamecq J., Latruffe N.Peroxisome proliferator-activated receptors (PPARs) and their implications in diseases. Curr Opin Endocrinol Diabetes Obes2000;7:8-18.
2.
Hsueh WA, Jackson S., Law REControl of vascular cell proliferation and migration by PPAR-γ . Diabetes Care2001;24:392-7.
3.
Picard F., Auwerx J.PPAR (gamma) and glucose homeostasis. Annu Rev Nutr2002;22:167-97.
4.
Gervois P., Fruchart JC, Staels B.Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists. Int J Clin Pract2004;58:22-9.
5.
Bocher V., Pineda-Torra I., Fruchart JC, Staels B.PPARs: Transcription factors controlling lipid and lipoprotein metabolism . Ann N Y Acad Sci2002;967:7-18.
6.
Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005; 28:1547-54.
7.
Vergès B.Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab2004;30:7-12.
8.
Qin S., Liu T., Kamanna VS, Kashyap MLPioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-α. Arterioscler Thromb Vasc Biol2007; 27:2428-34.
9.
Nissen SE, Wolsky K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007 ;356:2457-71.
10.
Lincoff AM, Wolski K., Nicholls SJ, Nissen SEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA2007;298:1180-8.
11.
Shetty C., Balasubramani M., Capps N. et al. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment . Diabet Med2007;24:94-7.
12.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA2001;285:2486-97.
Targett-Adams P., McElwee MJ, Ehrenborg E. et al. A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta2005; 1728:95-104.
15.
DiRenzo J., Soderstrom M., Kurokawa R. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol1997;17: 2166-76.
16.
Young PW, Buckle DR, Cantello Bcc et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther1998;284:751-9.
17.
Sakamoto J. , Kimura H., Moriyama S. et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone . Biochem Biophys Res Commun2000;278:704-11.
18.
Beghin L., Capps N., Duhal N. et al. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem1999;36:523-5.
19.
Savage R.Thiazolidinediones and lowered high density lipoprotein cholesterol . WHO Signal2005;(February):6-8.
20.
Senba H., Kawano M., Kawakami M.Severe decrease in serum HDL-Cholesterol during combination therapy of bezafibrate and pioglitazone. J Atheroscler Thromb2006 ;13:263-264.
21.
Lewis GF, Rader DJNew insights into regulation of HDL metabolism and reverse cholesterol transport . Circ Res2005;96:1221-32.
22.
Kiss RS, Kavaslar N., Okuhira K. et al. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol2007;27:1139-45.
